Access to hepatitis C treatment: a lesson for the future

Lucia Craxi', Lucia Craxì

Research output: Contribution to journalArticlepeer-review


The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.
Original languageEnglish
Pages (from-to)25-27
Number of pages3
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Access to hepatitis C treatment: a lesson for the future'. Together they form a unique fingerprint.

Cite this